Latest news with #Optejet
Business Insider
20-05-2025
- Business
- Business Insider
Eyenovia provides update on potential merger and Optejet development
Eyenovia (EYEN) provided updates on its potential merger with Betaliq and the ongoing development of its novel Optejet user filled device or UFD. Negotiations continue towards a binding merger agreement with Betaliq, a clinical-stage private pharmaceutical company focused on glaucoma with access to Eyesol, a non-aqueous technology that may address many of the needs of these patients. The companies have agreed to extend the binding exclusivity period set forth in the Letter of Intent until June 7 to allow more time to complete and execute the anticipated merger agreement. Progress in the development of the Optejet UFD continues and remains on track to file for U.S. regulatory approval in September of this year. An approval would provide for potential multiple commercial opportunities either directly with consumers or through eye care practitioner offices as well as potential and existing license partners, including Arctic Vision in China and Korea. A broad restructuring of the company was implemented, reducing overall cash burn by approximately 70% versus one year ago and entering into a debt restructuring agreement earlier this year which defers certain repayment obligations until October 2025.
Yahoo
19-05-2025
- Business
- Yahoo
Eyenovia Provides Updates on Potential Merger with Betaliq and Development of the Optejet User Filled Device (UFD), and Reports First Quarter 2025 Financial Results
Eyenovia and Betaliq continue to negotiate a binding merger agreement consistent with the previously announced signed Letter of Intent Reports continued progress on the development of the user-filled Optejet, and remains on track to file for U.S. device regulatory approval in September 2025 Reduced ongoing cash burn by approximately 70% versus prior year and improved debt repayment terms LAGUNA HILLS, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company developing the proprietary Optejet® topical ophthalmic medication dispensing platform, today provided updates on its potential merger with Betaliq and the ongoing development of its novel Optejet user filled device (UFD), and reported financial results for the first quarter ended March 31, 2025. Potential Merger with Betaliq Negotiations continue towards a binding merger agreement with Betaliq, a clinical-stage private pharmaceutical company focused on glaucoma with access to Eyesol®, a non-aqueous technology that may address many of the needs of these patients. We have agreed to extend the binding exclusivity period set forth in the Letter of Intent until June 7, 2025, to allow more time to complete and execute the anticipated merger agreement. Development of the Optejet UFD Progress in the development of the Optejet user-filled device (UFD) continues and remains on track to file for U.S. regulatory approval in September of this year. An approval would provide for potential multiple commercial opportunities either directly with consumers or through eye care practitioner offices as well as potential and existing license partners, including Arctic Vision in China and Korea. First Quarter 2025 Financials A broad restructuring of the company was implemented, reducing overall cash burn by approximately 70% versus one year ago and entering into a debt restructuring agreement earlier this year which defers certain repayment obligations until October 2025. Michael Rowe, Chief Executive Officer, commented, 'We remain focused on seeking to maximize shareholder value by working to complete a definitive merger agreement with Betaliq that, if and when completed, will create a new eyecare company with immediate revenue through the sale of our existing FDA-approved products and significant pipeline opportunities that we believe leverage complementary FDA-approved technologies, including our Optejet® platform.' 'At the same time, our engineering team continues to advance the development of our user-filled Optejet, which, if approved, would have the potential to address many of the shortcomings of traditional eyedrops, most notably ease of use and reduced waste. We look forward to submitting an application for device regulatory approval in September of this year and introducing this novel device that can deliver an enhanced experience across a broad range of uses.' 'In addition to these strategic initiatives, we took important measures over the past several months to reduce expenses, strengthen our balance sheet, and extend our cash runway. Perhaps the most notable of these is our entry into a debt restructuring agreement with Avenue Capital, which continues to be very supportive as we work toward finalizing a merger agreement with Betaliq. We look forward to the completion of this potential merger and believe we have set the stage for multiple value inflection points this year,' Mr. Rowe concluded. First Quarter 2025 Financial Review For the first quarter of 2025, net loss was $3.5 million, or $1.59 per share. This compares to a net loss of $10.9 million, or $18.75 per share, for the first quarter of 2024. Research and development expenses totaled $0.7 million for the first quarter of 2025, compared to $4.4 million for the first quarter of 2024, a decrease of 85%. For the first quarter of 2025, general and administrative expenses were $2.4 million, compared to $3.6 million for the first quarter of 2024, a decrease of 35%. Total operating expenses for the first quarter of 2025 were $3.0 million, compared to $10.1 million for the first quarter of 2024. This represents a decrease of 70%. As of March 31, 2025, the Company's unrestricted cash and cash equivalents were $3.9 million, as compared to $2.1 million in unrestricted and restricted cash as of December 31, 2024. About Eyenovia, Inc. Eyenovia, Inc. is an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform. The Optejet is especially useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may combine to produce better treatment options and outcomes for patients and providers. The Company's current commercial portfolio includes clobetasol propionate ophthalmic suspension, 0.05%, for post-surgical pain and inflammation, and Mydcombi® for mydriasis. For more information, please visit Forward Looking Statements Except for historical information, all the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to the potential transaction with Betaliq, our future activities or other future events or conditions, including those relating to the completion of due diligence on and a definitive transaction agreement with Betaliq, the estimated market opportunities for our platform technology, the timing for sales growth of our approved products, and the outcome of the process to explore strategic alternatives to maximize shareholder value. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to, among other things: the risk that the proposed transaction with Betaliq does not proceed; risks of our clinical trials, including, but not limited to, the potential advantages of our products, and platform technology; the rate and degree of market acceptance and clinical utility of our products; our estimates regarding the potential market opportunity for our products; reliance on third parties to develop and commercialize our products; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our products; intellectual property risks; changes in legal, regulatory, legislative and geopolitical environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products and product candidates; our competitive position; and our ability to raise additional funds and to make payments on our debt obligations as and when necessary. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements. Eyenovia Contact:Eyenovia, Lowenlowe@ Eyenovia Investor Contact:Eric RibnerLifeSci Advisors, LLCeric@ 751-4363EYENOVIA, INC. Condensed Balance Sheets March 31, December 31, 2025 2024 (unaudited) Assets Current Assets Cash and cash equivalents $ 3,934,966 $ 2,121,463 License fee and expense reimbursements receivable 25,787 24,827 Security deposits, current 14,968 14,968 Prepaid expenses and other current assets 1,183,262 605,941 Total Current Assets 5,158,983 2,767,199 Security deposits, non-current 182,200 182,200 Operating lease right-of-use asset 642,770 718,360 Total Assets $ 5,983,953 $ 3,667,759 Liabilities and Stockholders' Deficiency Current Liabilities: Accounts payable $ 1,199,961 $ 2,199,768 Accrued compensation 109,934 144,161 Accrued expenses and other current liabilities 3,241,554 3,178,513 Operating lease liabilities - current portion 542,561 575,163 Notes payable - current portion, net of debt discount of $56,954 and $527,870 as of March 31, 2025 and December 31, 2024, respectively 729,999 5,212,532 Convertible notes payable - current portion, net of debt discount of $723,725 and $263,930 as of March 31, 2025 and December 31, 2024, respectively 9,276,275 4,736,070 Total Current Liabilities 15,100,284 16,046,207 Operating lease liabilities - non-current portion 597,670 717,504 Total Liabilities 15,697,954 16,763,711 Stockholders' Deficiency: Preferred stock, $0.0001 par value, 6,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2025 and December 31, 2024 Common stock, $0.0001 par value, 300,000,000 shares authorized; 2,830,546 and 1,506,369 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively 283 151 Additional paid-in capital 189,079,241 182,213,889 Accumulated deficit (198,793,525 ) (195,309,992 ) Total Stockholders' Deficiency (9,714,001 ) (13,095,952 ) Total Liabilities and Stockholders' Deficiency $ 5,983,953 $ 3,667,759 EYENOVIA, INC. Condensed Statements of Operations (unaudited) For the Three Months Ended March 31, 2025 2024 Operating Income Revenue $ 14,720 $ 4,993 Cost of revenue (48 ) (203,027 ) Gross Profit 14,672 (198,034 ) Operating Expenses: Research and development 673,043 4,431,601 Selling, general and administrative 2,372,322 3,637,189 Reacquisition of license rights - 2,000,000 Total Operating Expenses 3,045,365 10,068,790 Loss From Operations (3,030,693 ) (10,266,824 ) Other Income (Expense): Other (expense) income, net 3,687 (97,558 ) Gain on debt extinguishment 89,623 - Interest expense (581,499 ) (678,658 ) Interest income 35,349 120,939 Total Other Expense (452,840 ) (655,277 ) Net Loss $ (3,483,533 ) $ (10,922,101 ) Net Loss Per Share - Basic and Diluted $ (1.59 ) $ (18.75 ) Shares Outstanding - Basic and Diluted 2,188,938 582,584 Sign in to access your portfolio
Yahoo
20-03-2025
- Business
- Yahoo
Eyenovia Shares Drop 14% Amid Betaliq Merger Talks
Eyenovia (EYEN, Financials) shares fell 14% to $1.44 as of 12:44 p.m. GMT-4 on Thursday after the company announced a non-binding letter of intent to merge with Betaliq, a clinical-stage pharmaceutical company specializing in glaucoma treatments. Warning! GuruFocus has detected 6 Warning Signs with EYEN. Combining Eyenovia's Optejet dispensing system with Betaliq's EyeSol medication delivery mechanism, the purchase would create a new publicly traded ophthalmology zero net cash upon closure, the acquisition values Betaliq at around $77 million and Eyenovia at almost $15 million. While Eyenovia owners would retain 16.3% on a fully diluted basis, Betaliq equity holders would control about 83.7% of the merged firms stated the acquisition is still under due consideration, board approvals, formal agreements, and financial contingency. About the timetable or completion of the merger, no guarantee was Betaliq's EyeSol technology seeks to increase bioavailability in glaucoma therapies, Eyenovia's Optejet platform is meant to improve ocular medication delivery. EyeSol has been licensed for use in FDA-approved eye care products, including MEIBOTM and VEVEYTM, the firms pointed said it would keep promoting its FDA-approved portfolio while looking for other in-licensing prospects to boost income. The business also is on schedule to submit for fourth quarter U.S. regulatory clearance of a user-filled Optejet the transaction is finalized, Eyenovia CEO Michael Rowe said the two technologies will be combined to enhance eye drug delivery. Barry Butler, CEO of Betaliq, said the mix offers a chance to increase glaucoma and other eye problem therapy Raymond James is representing Betaliq, Chardan is counseling Eyenovia on the offer. Eyenovia stated it does not intend to provide any updates unless a clear agreement is obtained or legal disclosure is mandated. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
20-03-2025
- Business
- Yahoo
Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq
Combination, if successful, would create a new publicly-listed eye care company combining Betaliq's EyeSol® water-free drug delivery technology for glaucoma with Eyenovia's Optejet® device platform The combined company would continue marketing Eyenovia's FDA-approved products – and plans to in-license additional products to generate near-term revenue NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) ('Eyenovia' or the 'Company'), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that it has entered into a non-binding letter of intent (LOI) contemplating a potential reverse merger transaction with Betaliq, Inc., a clinical stage pharmaceutical company with a therapeutic focus on glaucoma. The proposed merger would create a new ophthalmic company that combines two FDA-approved technologies: Betaliq's EyeSol® water-free drug delivery technology for use in glaucoma, and Eyenovia's Optejet topical ophthalmic liquid dispensing platform. The proposed transaction remains subject to completion of mutually satisfactory due diligence, the negotiation and execution of definitive agreements on mutually satisfactory terms, the approval of such definitive documentation by the boards of directors of both Eyenovia and Betaliq, and the completion of necessary financing contingencies. There can be no assurance that any such agreement will be executed or the proposed transaction with Betaliq will be consummated, or as to the timing of the entry of any such agreement or the consummation of such proposed transaction. The proposed transaction assumes a value for Betaliq of approximately $77 million and a value for Eyenovia of approximately $15 million, assuming zero cash (net of liabilities) at merger closing. The exchange ratio is intended to result in Betaliq equity holders owning approximately 83.7% of the combined company, while Eyenovia equity holders would own approximately 16.3% at the closing of the merger, on a fully diluted basis. Betaliq's EyeSol technology offers increased bioavailability and a drop size of 10 microliters that can be replicated in the Optejet device. The EyeSol technology is currently used and licensed in FDA-approved topical eye care medications, including MEIBO™ (perfluorohexyloctane ophthalmic solution, Bausch + Lomb) and VEVYE™ (cyclosporine ophthalmic solution 0.1%, Harrow) Eyenovia's Optejet dispensing platform, in addition to providing similar benefits to those provided by EyeSol, also may enhance the performance of products by making it easier to use and comply with therapy. Importantly, EyeSol is compatible with the Optejet. Eyenovia continues to advance development of the user-filled Optejet and remains on track to file for U.S. regulatory approval in the fourth quarter of this year. The user-filled Optejet is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. 'Following a review of strategic alternatives that we initiated in January, I, along with my fellow Board members, concluded that continuing the negotiation of this potential merger with Betaliq is in the best interests of our company, our team members, patients and shareholders,' stated Michael Rowe, Chief Executive Officer of Eyenovia. 'Under a combined new company, if the transaction is completed, our existing products could continue to be marketed to ophthalmologists and optometrists, while the combination of the EyeSol and Optejet technologies has the potential to create a platform that could fundamentally improve how topical eye medications and products are administered. We look forward to working with the Betaliq team on the completion of due diligence and the negotiation and potential execution of a definitive merger agreement in the coming weeks.' Barry Butler, Chief Executive Officer of Betaliq, added, 'This proposed merger with Eyenovia represents a significant opportunity in the eyecare space. The inherent synergies of the EyeSol and Optejet technologies could bring innovative new treatment options to patients with glaucoma as well as other ocular diseases. By leveraging the existing pipelines of Eyenovia and Betaliq with multiple opportunities for pipeline expansion through established partnerships, we believe we can build a leading ophthalmic company.' Eyenovia does not intend to discuss or disclose further developments regarding these discussions unless and until such definitive agreement is executed or its Board of Directors has otherwise determined that further disclosure is appropriate or required by law. Chardan is acting as advisor to Eyenovia in connection with the proposed transaction. Raymond James is acting as an advisor to Betaliq. About Betaliq, Inc., is a clinical stage pharmaceutical company with a therapeutic focus on Glaucoma, founded in 2018 through a collaboration with Novaliq GmbH. Betaliq is developing a global portfolio of topical glaucoma treatments based on the unique EyeSol® topical delivery system developed by Novaliq. This unique water-free eye drop technology offers increased residency time and enhanced bioavailability to provide the needed efficacy, while using less total drug. EyeSol® based eye drops are non-preserved not containing any chemical preservatives, like benzalkonium chloride, that can cause damage to the ocular surface, while being dispensed in a traditional multi-dose eye drop bottle. For more information, please visit About Eyenovia, Inc. is an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform. The Optejet is especially useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may combine to produce better treatment options and outcomes for patients and providers. The company's current commercial portfolio includes clobetasol propionate ophthalmic suspension, 0.05%, for post-surgical pain and inflammation, and Mydcombi® for mydriasis. For more information, please visit Forward Looking StatementsExcept for historical information, all the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to the potential transaction with Betaliq, our future activities or other future events or conditions, including those relating to the completion of due diligence on and a definitive transaction agreement with Betaliq, the estimated market opportunities for our platform technology, the timing for sales growth of our approved products, and the outcome of the process to explore strategic alternatives to maximize shareholder value. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to, among other things: the risk that the proposed transaction with Betaliq does not proceed; risks of our clinical trials, including, but not limited to, the potential advantages of our products, and platform technology; the rate and degree of market acceptance and clinical utility of our products; our estimates regarding the potential market opportunity for our products; reliance on third parties to develop and commercialize our products; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our products; intellectual property risks; changes in legal, regulatory, legislative and geopolitical environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products and product candidates; our competitive position; and our ability to raise additional funds and to make payments on our debt obligations as and when necessary. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements. Eyenovia Contact:Eyenovia, LoweVice President, Commercial Operationsnlowe@ Betaliq Contact:Betaliq, ButlerChief Executive Officerbbutler@ Eyenovia Investor Contact:Eric RibnerLifeSci Advisors, LLCeric@ 751-4363 Sign in to access your portfolio
Globe and Mail
19-03-2025
- Business
- Globe and Mail
Myopia Treatment Devices Market is expected to Grow at a CAGR of 7.57% During the Study Period (2021-30), estimates DelveInsight
"Myopia Treatment Devices Market" Myopia Treatment Devices companies such as CooperVision (CooperCompanies), Johnson & Johnson, Essilor, Bausch & Lomb Incorporated, Menicon Co., Ltd., LUCID KOREA LTD., Alcon Inc., HOYA VISION CARE COMPANY, SynergEyes., SightGlass Vision, Inc., Ophtec BV, STAAR SURGICAL, Mark'ennovy, SCHWIND eye-tech-solutions, Euclid Systems Corporation, NIDEK USA, Inc., HORUS S.n.C. di Risoldi & C – P, Falco lenses AG, and others. (Albany, USA) According to the latest report published by DelveInsight 'Myopia Treatment Devices Market Insight,' the global Myopia Treatment Devices Market is anticipated to witness stellar growth owing to the rising government initiatives to raise awareness among the population regarding myopia treatment, increase in myopia affected cases across the globe, rise in product launches of various advanced myopia management devices. This report will provide an in-depth understanding of the Myopia Treatment Devices market which will further benefit the competitors or stakeholders operating in the Myopia Treatment Devices market. The Myopia Treatment Devices market is anticipated to boost as the demand for these devices is increasing at a considerable rate owing to the rising prevalence of myopia, worldwide. Additionally, an increase in the adoption rate of Myopia Treatment Devices is further expected to bolster the global market for Myopia Treatment Devices during the forecast period (2024-2030). Key Takeaways from the Myopia Treatment Devices Market Report As per DelveInsight estimates, APAC is anticipated to dominate the global Myopia Treatment Devices market during the forecast period. The leading Myopia Treatment Devices companies such as CooperVision (CooperCompanies), Johnson & Johnson, Essilor, Bausch & Lomb Incorporated, Menicon Co., Ltd., LUCID KOREA LTD., Alcon Inc., HOYA VISION CARE COMPANY, SynergEyes., SightGlass Vision, Inc., Ophtec BV, STAAR SURGICAL, Mark'ennovy, SCHWIND eye-tech-solutions, Euclid Systems Corporation, NIDEK USA, Inc., HORUS S.n.C. di Risoldi & C – P, Falco lenses AG, and others are currently working in the Myopia Treatment Devices market. In January 2024, Eyenovia, Inc., a commercial-stage, ophthalmic company, announced that it has re-acquired the rights to MicroPine in the U.S. and Canada. MicroPine, an investigational eight microliter ophthalmic spray of atropine delivered by Eyenovia's proprietary Optejet device, is being evaluated as a potential treatment for pediatric progressive myopia which is characterized by elongation of the sclera/retina. In October 2023, NIDEK CO LTD launched the NP-1/NP-1C Preloaded IOL Injection System. The NP-1/NP-1C is a fully preloaded injection system with an aspheric hydrophobic soft acrylic lens designed for smoother, safer, and secure IOL implantation. This newly developed injector is designed for smooth, controlled delivery. The NP-1/NP-1C allows quick and easy operation using a simple two-step process involving, filling the viscoelastic material and pressing the plunger. On May 25, 2021, CooperVision DreamLite® Ortho-K Lenses gained European approval for slowing the progression of myopia. On May 12, 2021, Euclid Systems Corporation, a global leader in advanced orthokeratology and proactive myopia management, launched the latest breakthrough in overnight orthokeratology lens, Euclid MAX in the US. On April 07, 2021, Menicon entered into a global collaboration with Johnson & Johnson Vision to bring forward therapeutic contact lens-related products and services to manage the progression of myopia in children. Thus, owing to such developments in the market, there will be rapid growth observed in the Myopia Treatment Devices market during the forecast period. To read more about the latest highlights related to Myopia Treatment Devices, get a snapshot of the key highlights entailed in the Myopia Treatment Devices Market Report Myopia Treatment Devices Myopia, or near-sightedness is a refractive vision disorder that causes blurred sight at a distance. It occurs when the length of the eye (known as axial length) is too great; myopia progresses as axial length increases with age. The devices such as eyeglasses, contact lenses, and Ortho-K lenses, among others which are used to slow down the progression of myopia are termed myopia treatment devices. Children who are at high risk of progressive myopia (due to a family history of the condition, early age of onset, and lengthy durations of close work) may benefit from treatment options that have been found to slow the advancement of myopia. These treatments for myopia include bifocal spectacle or contact lens prescription, orthokeratology, eye drops, or a combination of these. Myopia control may assist protect eye health since those with extreme myopia are more likely to develop cataracts, glaucoma, and myopic macular degeneration. Myopia Treatment Devices Market Insights Geographically, the global Myopia Treatment Devices market is studied for North America, Europe, Asia-Pacific, and the Rest of the World. APAC is projected to witness the fastest growth during the study period. This is owing to the rising prevalence of the targeted population. Moreover, rising government initiatives to raise awareness regarding the proper management of myopia among the population in the region is also a potential factor for Myopia Treatment Devices market growth. Furthermore, the presence of regional companies such as Menicon Co., Ltd., Kubota Pharmaceutical Holdings Co., Ltd., among others, and their increased focus on developing novel Myopia treatment options will also contribute to the fastest Myopia Treatment Devices market growth in the region. For instance, Kubota Pharmaceutical Holdings Co., Ltd. with its subsidiary Kubota Vision is planning to use the Kubota Glass technology which leverages nanotechnology in an electronic glasses-based device to reduce the progression of myopia by actively stimulating the retina for shorter periods while maintaining high-quality central vision and not affecting daily activities to develop smart contact lenses for the reduction of myopia progression. To know more about why APAC is leading the market growth in the Small Myopia Treatment Devices market, get a snapshot of the report Myopia Treatment Devices Market Myopia Treatment Devices Market Dynamics The Myopia Treatment Devices market is gaining pace at present owing to the growing myopia cases across the globe. Furthermore, approval of various myopia treatment devices in various countries across the globe to slow down the progression of the disease is also projected to augment the Myopia Treatment Devices market in the upcoming years. For instance, on June 03, 2020, SightGlass Vision achieved CE Mark allowing European Marketing Authorization for novel eyeglasses that slow myopia progression in children. The spectacles developed by the company comprise advanced diffusion optics technology spectacle lenses. Hence, the above-mentioned factors are expected to increase the Myopia Treatment Devices market in the future. However, limitations associated with the refractive surgery procedures and stringent regulatory approval process for the myopia treatment devices are likely to impede the growth of the Myopia Treatment Devices market. Moreover, the unprecedented COVID-19 impact had sluggish the Myopia Treatment Devices market growth. This is due to the implementation of stringent lockdowns across the nation, and the reduction in clinic visits due to reluctance among patients during the pandemic, among others. However, a sudden shift toward digital or e-learning approaches from classroom-based learning has subsequently increased myopia and its progression among the students. For instance, as per the report published by UNESCO in the year 2020, approximately 1.37 billion students from more than 130 countries globally were affected by the pandemic as the schools and universities adopted digital learning during the pandemic to curb the infection. Thus, it is expected to increase the risk of myopia among the children which will increase the demand for the myopia treatment devices during the post-pandemic situation, thus the Myopia Treatment Devices market will gain normalcy. Scope of the Myopia Treatment Devices Market Report Coverage: Global Study Period: 2021-2030 Market Segmentation By Treatment - Corrective Lenses, Laser Eye Surgery, Lens Implant Surgery Market Segmentation By Product Type - Eyeglasses, Contact Lenses, Ortho-K Lenses, Phakic Intraocular Lenses, Excimer Laser Refractive Surgery Devices Market Segmentation By End-User - Hospitals, Specialty Clinics, and Others Market Segmentation By Geography - North America, Europe, Asia-Pacific, and Rest of World Key Myopia Treatment Devices Companies - CooperVision (CooperCompanies), Johnson & Johnson, Essilor, Bausch & Lomb Incorporated, Menicon Co., Ltd., LUCID KOREA LTD., Alcon Inc., HOYA VISION CARE COMPANY, SynergEyes., SightGlass Vision, Inc., Ophtec BV, STAAR SURGICAL, Mark'ennovy, SCHWIND eye-tech-solutions, Euclid Systems Corporation, NIDEK USA, Inc., HORUS S.n.C. di Risoldi & C – P, Falco lenses AG, among others Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View DelveInsight Analysis: The Myopia Treatment Devices market size is expected to grow at a CAGR of 7.57% during the study period (2021-30). Table of Contents 1. Report Introduction 2. Executive summary 3. Regulatory and Patent Analysis 4. Key Factors Analysis 5. Porter's Five Forces Analysis 6. COVID-19 Impact Analysis on Myopia Treatment Devices Market 7. Myopia Treatment Devices Market Layout 8. Global Company Share Analysis – Key 3-5 Companies 9. Myopia Treatment Devices Market Company and Product Profiles 10. Project Approach 11. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
